| Identification | Back Directory | [Name]
N(L-TYROSINE)-9Z,12Z,15Z-OCTADECATRIENAMIDE | [CAS]
259143-19-6 | [Synonyms]
NALT
N-(α-Linolenoyl) Tyrosine
N-(α-Linolenoyl) Tyrosine
DEQLZTQITSWABQ-GMOGWPNXSA-N
N-(ALPHA-LINOLEOYL) TYROSINE
N-(.alpha.-Linolenoyl) Tyrosine
N(L-TYROSINE)-9Z,12Z,15Z-OCTADECATRIENAMIDE
N (α Linolenoyl) Tyrosine,N(αLinolenoyl) Tyrosine
L-Tyrosine, N-[(9Z,12Z,15Z)-1-oxo-9,12,15-octadecatrien-1-yl]- | [Molecular Formula]
C27H39NO4 | [MDL Number]
MFCD08062216 | [MOL File]
259143-19-6.mol | [Molecular Weight]
441.6 |
| Hazard Information | Back Directory | [Description]
Certain chronic neurologic disorders, such as Parkinson’s disease, are caused by an insufficiency of the neurotransmitter dopamine secondary to the degeneration of substantia nigra dopaminergic neurons.1 N-(α-Linolenoyl) tyrosine (NALT) is a simple α-amide conjugate between the ω-3 essential fatty acid α-linolenate and the amino acid tyrosine. α-Linolenate is an important precursor to docosahexaenoic acid (DHA), a prominent brain polyunsaturated fatty acid, while tyrosine is the metabolic precursor for neuronal dopamine synthesis. NALT was prepared as a method for enhancing central nervous system (CNS) dopamine content by facilitated transport of the tyrosine precursor across the blood-brain barrier.2 In experimental rat models of dopamine insufficiency, NALT increased CNS dopamine levels and exhibited an activity profile consistent with an anti-Parkinson’s therapeutic agent.2 | [Definition]
ChEBI: N-(alpha-Linolenoyl) Tyrosine is a tyrosine derivative. | [References]
1. Martin, J.B. Molecular basis of the neurodegenerative disorders N. Engl. J. Med. 340(25),1970-1980(1999).
2. Yehuda, S. Possible anti-Parkinson properties of N-(α-linolenoyl) tyrosine: A new molecule Pharmacol. Biochem. Behav. 72(1-2),7-11(2002). |
|
|